Rezolute announces presentation of Phase 2 RIZE study sub-analyses

Rezolute announced that a poster titled “An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 Study” will be presented at the Pediatric Endocrine Society Annual Meeting, to be held May 2-5, 2024 at the Sheraton Grand Chicago Riverwalk. Paul Thorton, M.D., of Cook Children’s Medical Center in Fort Worth, Texas, will present the poster, which details findings from the Company’s Phase 2 RIZE study evaluating the treatment of congenital hyperinsulinism with RZ358 in pediatric patients. While primary and key secondary glycemic endpoints from the RZ358-606 study have been previously reported, the current sub-analyses highlight the benefits of RZ358 during the vulnerable overnight fasting period, utilizing continuous glucose monitor to evaluate average time in hypoglycemia and average glucose levels overnight. These and previously reported results, including improvements in overall hypoglycemia events and time of up to ~90% at the top doses, suggest that RZ358 has the potential to be a safe and effective therapy to treat all forms of congenital HI. A Phase 3 study is currently underway.